Fig. 1: First-in-human dynamic ¹⁸F-pretomanid PET/CT studies in human subjects.

Eight subjects were prospectively enrolled and imaged in accordance with the U.S. Food and Drug Administration guidelines (NCT05609552). a ¹⁸F-Pretomanid PET area under the curve (AUC) heatmap overlay on computed tomography (CT) of a representative subject with pulmonary TB (subject 7). b Coronal CT section from the same subject showing the volumes of interest (VOI) used to quantify the ¹⁸F-pretomanid PET signal and obtain time-activity curves from different tissues (panel c). d ¹⁸F-Pretomanid AUC heatmap overlay on CT of a representative healthy subject (subject 2). e Coronal CT section from the same subject showing the volumes of interest (VOI) used to quantify the ¹⁸F-pretomanid PET signal and obtain time-activity curves from different tissues (panel f). g ¹⁸F-Pretomanid (tissue-to-plasma) AUC_0-60min ratios from all subjects demonstrate significantly higher brain versus lung tissue exposures (P < 0.001). Circles and squares represent female and male subjects respectively. Empty shapes represent TB patients. n = 2 VOI per tissue per subject (n = 16 brain, n = 16 lung). Data are represented as median ± interquartile range. Statistical comparisons were made using a two-tailed Mann-Whitney U test. Source data are provided as a Source Data file.